← Back to Search

Serotonin-Norepinephrine Reuptake Inhibitor

A for Menopause (DVS Trial)

Phase 3
Waitlist Available
Led By Claudio N Soares, MD, PhD
Research Sponsored by Hamilton Health Sciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Pivotal Trial

Summary

This trial investigates the effects of Desvenlafaxine succinate on brain function and structure in midlife men and women with depression. It also examines if the medication can help with menopausal symptoms like hot flashes and night sweats in women. Desvenlafaxine succinate has been studied for its efficacy in treating menopausal symptoms, such as hot flashes, in addition to its use for major depressive disorder.

Eligible Conditions
  • Depression
  • Menopause

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2015 Phase 4 trial • 53 Patients • NCT01916824
21%
Headache
17%
Insomnia
13%
Upper Respiratory Tract Infection
8%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Participants With Major Depressive Disorder
Healthy Controls

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AExperimental Treatment1 Intervention
Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Desvenlafaxine
FDA approved

Find a Location

Who is running the clinical trial?

Hamilton Health Sciences CorporationLead Sponsor
377 Previous Clinical Trials
340,310 Total Patients Enrolled
Wyeth is now a wholly owned subsidiary of PfizerIndustry Sponsor
625 Previous Clinical Trials
248,349 Total Patients Enrolled
6 Trials studying Menopause
1,559 Patients Enrolled for Menopause
St. Joseph's Healthcare HamiltonOTHER
200 Previous Clinical Trials
26,719 Total Patients Enrolled
2 Trials studying Menopause
57 Patients Enrolled for Menopause
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top